Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2020) M. Pavel et al.   ANNALS OF ONCOLOGY

Antiproliferative Effect Of Above-Label Doses Of Somatostatin Analogs For The Management Of Gastroenteropancreatic Neuroendocrine Tumors

(2020) Leonidas Diamantopoulos et al.   NEUROENDOCRINOLOGY

Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor

(2019) Giuseppe Lamberti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors

(2018) Sally C. Lau et al.   MEDICAL ONCOLOGY

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

(2017) Jonathan Strosberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Peptide receptor radionuclide therapy in the management of gastrointestinal neuroendocrine tumors: efficacy profile, safety, and quality of life

(2017) Stefano Severi et al.   OncoTargets and Therapy

Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

(2016) James C Yao et al.   LANCET

ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site

(2016) M. Pavel et al.   NEUROENDOCRINOLOGY

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

(2014) Martyn E. Caplin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors

(2012) Maxime Palazzo et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

(2011) Marianne E Pavel et al.   LANCET

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)

(2011) M. Herdman et al.   QUALITY OF LIFE RESEARCH

Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30

(2010) Kim Cocks et al.   JOURNAL OF CLINICAL ONCOLOGY